Latest / Bloomberg Law / Allergan Patents Invalidated by U.S. Judge (Audio)
Transcript
- 0:00Speaker 1: A serious legal blow to one of Allergan's blockbuster drugs.
- 0:03Speaker 1: A federal judge has invalidated Allergan's patents for one of
- 0:06Speaker 1: its best selling drugs, Ristasis. Judge William Bryson also criticized
- 0:11Speaker 1: Allergan's novel and controversial deal with the Saint Regis Mohawk
- 0:15Speaker 1: tribe to take advantage of the tribe's sovereign immunity to
- 0:18Speaker 1: game the system. Milon and Teva pharmaceutical are seeking to
- 0:22Speaker 1: sell generic versions of Ristasis, but they don't have regulatory
- 0:25Speaker 1: approval yet. The skyrocketing costs of prescription drugs are part
- 0:29Speaker 1: of the healthcare debate. On Monday, President Trump said the
- 0:32Speaker 1: drug companies were getting away with murder. The same exact
- 0:36Speaker 1: pill from the same company, the same box, same everything
- 0:40Speaker 1: is a tiny fraction of what a court in the
- 0:42Speaker 1: United says. We are going to get drug prices, prescription
- 0:45Speaker 1: drug prices way down because the world has taken advantage
- 0:49Speaker 1: of us. Allergan is appealing the decision. Joining us are
- 0:53Speaker 1: Michael Carrier, professor at Rutgers University Law School, and Ode Gersbacker,
- 0:58Speaker 1: Bloomberg News senior Lytic Asian analyst oh tell Us about
- 1:02Speaker 1: Judge Bryson's decision on the patents. Okay, so there there
- 1:07Speaker 1: are really two decisions yesterday that came down, um, one
- 1:10Speaker 1: on the patents, invalidating all of them, so that really
- 1:14Speaker 1: clears the way for generics. And the other was the
- 1:17Speaker 1: decision to actually join the tribe to the lawsuit. Could
- 1:22Speaker 1: you could you explain what the decision was based on
- 1:25Speaker 1: the tribe decision? No, the decision on the patents. On
- 1:29Speaker 1: the patents, I'm sorry. Um, So the patents were invalidated
- 1:33Speaker 1: for um, what we call obviousness in patent law, and
- 1:36Speaker 1: that just means that the judge found that prior to
- 1:41Speaker 1: elegant filing these patent applications that eventually became patents, the
- 1:46Speaker 1: the invention had already been um made or discovered or
- 1:49Speaker 1: written about in different pieces of literature. Mike tell us
- 1:54Speaker 1: about the other decision, Uh so, um that he could
- 1:58Speaker 1: have stopped. I guess that one decision that ode was
- 2:01Speaker 1: just talking about invalidating the patents, but he also wrote
- 2:04Speaker 1: something separate that talked about what he called a ploy
- 2:08Speaker 1: to transfer the patents to a Native American trap tell
- 2:12Speaker 1: us a little bit about that issue, if you would.
- 2:15Speaker 1: So that question was whether or not Allergun's motion would
- 2:18Speaker 1: be granted to join a party to join the tribe
- 2:21Speaker 1: to the lawsuit. At the end of the day, the
- 2:24Speaker 1: court said, yet, because it wasn't willing to take the
- 2:26Speaker 1: chance that by not joining the tribe, eventually the decision
- 2:30Speaker 1: could be thrown out if the tribe really did play
- 2:32Speaker 1: a role, a valid role in this transaction. So the
- 2:36Speaker 1: court was really being conservative in saying, there's a chance
- 2:39Speaker 1: that the tribe could play a role, so I will
- 2:42Speaker 1: allow them to join the case. But in doing that,
- 2:46Speaker 1: to Judge was as clear as I have ever seen
- 2:48Speaker 1: in a court opinion that this is basically a sham transaction,
- 2:52Speaker 1: and there was tons of language that made that clear.
- 2:55Speaker 1: Judge Bryson said, in reality, it's paid the tribe to
- 2:59Speaker 1: allow are going to purchase, or perhaps more precisely, to rent,
- 3:03Speaker 1: the tribe's sovereign immunity in order to defeat the pending
- 3:06Speaker 1: i PR proceedings in the p g O. So oh,
- 3:09Speaker 1: tell us about the i PR proceedings, what they are,
- 3:13Speaker 1: and why Allergan was so anxious to have the tribe
- 3:17Speaker 1: in that part of it. So the i p R
- 3:20Speaker 1: s are fairly new proceeding um that I can invalidate
- 3:24Speaker 1: a patent outside of the court. It's really just the
- 3:26Speaker 1: patent office rethinking its decision of granting a patent um
- 3:31Speaker 1: And we've seen this, especially in the pharmaceutical industry. We've
- 3:34Speaker 1: had that as an issue for the last couple of years,
- 3:37Speaker 1: and it's it's easier to actually invalidate patents at that
- 3:40Speaker 1: level than it is in court for various reasons. Um
- 3:43Speaker 1: and there is an interplay between the two, so that
- 3:46Speaker 1: if the patent office invalidates a patent and that actually
- 3:49Speaker 1: survives on appeal and the patent is validated, then it
- 3:52Speaker 1: is no longer at play in the court, and then
- 3:55Speaker 1: vice versa. If this, if this decision stands and then
- 3:59Speaker 1: it actually as on appeal, then that will actually be binding. So, Mike,
- 4:04Speaker 1: why why would Allergan want to transfer the patent to
- 4:08Speaker 1: the st regious tribe? What what did that do that
- 4:12Speaker 1: let them get out from under or try to get
- 4:14Speaker 1: out from under the I p R proceeding. The primary
- 4:18Speaker 1: reason is that it allows them to make an argument
- 4:21Speaker 1: that they are now immune from having their patents challenged.
- 4:25Speaker 1: Sovereign immunity is a doctrine that goes back centuries and
- 4:29Speaker 1: the reason is that state. Historically we're not able to
- 4:32Speaker 1: be sued. Tribal sovereign immunity is a little different. It
- 4:35Speaker 1: doesn't have the same exact basis. But the point here
- 4:38Speaker 1: is that Allergan was trying to transfer the patents to
- 4:42Speaker 1: the Native American tribe so that the tribe would be immune.
- 4:46Speaker 1: So if generics were challenging the patents at the patent office,
- 4:50Speaker 1: then they can say you're out of luck. The game's
- 4:52Speaker 1: over because we are immune from suit. We're talking about
- 4:56Speaker 1: a judge invalidating the patents covering Allergan's hoops selling eye
- 5:00Speaker 1: drug stasis with Michael Carrier, professor at Rutgers University Law
- 5:05Speaker 1: School and ode gers Backer, Bloomberg News senior litigation analyst
- 5:10Speaker 1: Michael where there's a two track review process going on
- 5:13Speaker 1: by the district court, the federal courts there and the
- 5:16Speaker 1: Patent Trial and Appeal Board and different standards, and so
- 5:21Speaker 1: many patents have been invalidated by the Patent Trail and
- 5:24Speaker 1: Appeal Board that it's been called a death squad. And
- 5:27Speaker 1: that was first coined by the former Chief Judge of
- 5:30Speaker 1: the Court of Appeals, which oversees the patent disputes in
- 5:33Speaker 1: the country. Randall Radar. So explain the different legal standards
- 5:38Speaker 1: and why the double track. So there are different standards
- 5:43Speaker 1: in what you need to show to show that the
- 5:46Speaker 1: patent is not valid. So in the patent office, in particular,
- 5:50Speaker 1: in front of what's done a stab the appellate board,
- 5:52Speaker 1: you have to show by a reponderance of the evidence,
- 5:55Speaker 1: in other words, that the patent should not have been granted.
- 5:59Speaker 1: In contrast, in federal court it's a higher standard. You
- 6:01Speaker 1: have to show by clear and convincing evidence that the
- 6:04Speaker 1: patent should not have been granted. And so you see
- 6:06Speaker 1: what that difference. That it's possible for a patent to
- 6:09Speaker 1: be overturned at the patent office proceeding while still not
- 6:15Speaker 1: being overturned in federal courts. So many parents say that
- 6:19Speaker 1: it is a death squad and these patents never survived.
- 6:23Speaker 1: On the other hand, many patents should not have beenished
- 6:26Speaker 1: in the first place. Time examiners have a very short
- 6:28Speaker 1: period of time to look at these. So maybe this
- 6:31Speaker 1: is the right answer what the key tap is doing.
- 6:35Speaker 1: And oh, just so we're clear on on how that
- 6:37Speaker 1: all applies to Allergan. Allergan has has this case in
- 6:40Speaker 1: district court where we have the ruling this week, and
- 6:43Speaker 1: it's got a proceeding at p TAB To to preserve
- 6:46Speaker 1: its patents on this drug, does Allergant have to win
- 6:49Speaker 1: both of those cases. So to preserve it, Allergan has
- 6:52Speaker 1: to win on appeal. Um. The patent trial and Appeal
- 6:57Speaker 1: Board decisions and the Trick Court decisions all get moved
- 7:02Speaker 1: up to the Federal Circuit Court of Appeals, which makes
- 7:05Speaker 1: a decision pretty much final decision unless it goes to
- 7:08Speaker 1: the Supreme Court. So as it stands right now, the
- 7:11Speaker 1: patents are invalidated by the court, which um will We'll
- 7:15Speaker 1: get appeal or has been appealed when that decision comes down.
- 7:19Speaker 1: If they're upheld, then we can look back at the
- 7:21Speaker 1: i p R and see if it gets invalidated there.
- 7:24Speaker 1: But if if um, if that, if Elegant doesn't succeed
- 7:28Speaker 1: on appeal, then they're invalidated and the i prs really
- 7:31Speaker 1: don't matter. Michael, can you talk a little bit about
- 7:35Speaker 1: how difficult it is to make a drug like this
- 7:40Speaker 1: into a generic, In other words, how long it would
- 7:42Speaker 1: take before Milon and Teva could actually get a generic
- 7:48Speaker 1: on the market. So one of the difficulties here is
- 7:53Speaker 1: that there are shifting standards. So initially there was a
- 7:57Speaker 1: talent that covered with spaces. It was did a couple
- 8:00Speaker 1: of decades ago, and it expired in and then Allergan
- 8:05Speaker 1: got a second wave of patents, and so that wave
- 8:08Speaker 1: of patents has been keeping the generics off the market.
- 8:11Speaker 1: The generics also need FDA approval. That second wave of
- 8:14Speaker 1: patents was what was just invalidated by the district court yesterday.
- 8:18Speaker 1: But still the generic has to get FDA approval and
- 8:21Speaker 1: that process could take a couple of years. And so
- 8:24Speaker 1: even though the patents were invalidated, generics are not about
- 8:27Speaker 1: to enter the market immediately. Oh. One of the other
- 8:31Speaker 1: perhaps confusing, perhaps intriguing aspects of this case is that
- 8:34Speaker 1: the judge in the in the district court, Judge Bryson,
- 8:38Speaker 1: is actually a judge on that federal appeals court that
- 8:41Speaker 1: handles patent case. But he cases but he was sitting
- 8:45Speaker 1: by designation in this at the district court level. Tell
- 8:47Speaker 1: us a little bit about him and whether he is
- 8:50Speaker 1: opinion on the subject of the Native American tribe might
- 8:54Speaker 1: be influential with his colleagues on the federal circuit. Yes,
- 8:57Speaker 1: I mean, it's very interesting that Federal Circuit judge would
- 9:01Speaker 1: come would have this decision um. I definitely think that
- 9:05Speaker 1: that also contributed to the length of the opinion on
- 9:08Speaker 1: on the motion elegant um um got granted, eventually adding
- 9:12Speaker 1: the tribe. You know, he pretty much lays out the
- 9:15Speaker 1: argument for the p TAB and eventually that that decision
- 9:19Speaker 1: will get reviewed by the Federal Circuit. So I definitely
- 9:22Speaker 1: think that he is one who knows patent law. I mean,
- 9:26Speaker 1: he's on the court that reviews all patent decisions, and
- 9:28Speaker 1: that will definitely influence the court. Michael the In June,
- 9:34Speaker 1: the Supreme Court agreed to take a case to determine
- 9:37Speaker 1: if these p TAB reviews are constitutional. Tell us a
- 9:40Speaker 1: little bit about that and where you see that going
- 9:43Speaker 1: or how you see that going. So Algan said that
- 9:47Speaker 1: they don't want to be subject to double jeopardy by
- 9:50Speaker 1: having their patent scrutinized not only in the courts, but
- 9:53Speaker 1: at the TAB as well. Double jeopardy doesn't really apply
- 9:57Speaker 1: your it's more of a criminal concept. They are saying
- 10:01Speaker 1: that it's not there for the patent office to overturn patents.
- 10:06Speaker 1: If that's something for the court to do. I don't
- 10:08Speaker 1: think that argument will be effective at the Supreme Court
- 10:13Speaker 1: later this year. And the reason is that patents don't
- 10:17Speaker 1: fall from the sky. There's no natural right to patents.
- 10:20Speaker 1: They're created by Congress, and Congress can create the mechanism
- 10:24Speaker 1: by which patents can be reviewed. And for several decades,
- 10:27Speaker 1: Congress has said that patents can be reviewed by the
- 10:31Speaker 1: Patent Office in these perceivings. After the American Events Act
- 10:35Speaker 1: in twenty eleven, the form of the proceedings changed a bit,
- 10:39Speaker 1: but nonetheless it's still Congress saying, Okay, Patent Office, take
- 10:42Speaker 1: a second look at these things. Maybe you didn't get
- 10:44Speaker 1: right the first time. Litigation is so expensively so long
- 10:49Speaker 1: that the second look is fine. And so I think
- 10:50Speaker 1: that's what the Extreme Court will say, that this is constitutional.
- 10:54Speaker 1: Oh only about thirty seconds. But Wayne on the Supreme
- 10:57Speaker 1: Court case, how significant is that in the world of
- 10:59Speaker 1: patent law. Yeah, I mean, I agree actually with Michael,
- 11:02Speaker 1: because we've had these kinds of proceedings already, right, we
- 11:05Speaker 1: have re examinations, We've had different iterations of this. This
- 11:09Speaker 1: is just a new iteration. So I agree with that.
- 11:13Speaker 1: I want to thank you both for being on Bloomberg Law.
- 11:15Speaker 1: It's a really interesting case and so many facets we
- 11:18Speaker 1: could go on for a long time. That's Ogre s Backer.
- 11:20Speaker 1: She's a Bloomberg News senior litigation analyst. And Michael Carrier,
- 11:24Speaker 1: he's a professor at Rutgers University Law School. Coming up,
- 11:28Speaker 1: we're going to be talking about Colin Kaepernick, who started
- 11:31Speaker 1: the national anthem protests that are now causing such controversy
- 11:35Speaker 1: in the NFL that the owners are going to be
- 11:37Speaker 1: discussing them at their meetings today and tomorrow. Now, he's
- 11:41Speaker 1: filed a grievance accusing the NFL of colluding to keep
- 11:45Speaker 1: him out of the league because of that national anthem protest.
- 11:49Speaker 1: But he faces a really tough legal hurdle. We're gonna
- 11:52Speaker 1: be discussing that hurdle coming up. This is Bloomberg. Thank